Astrazeneca PLC (AZN): Price and Financial Metrics
Astrazeneca PLC (AZN)
Today's Latest Price: $42.47 USD
Updated Mar 27 12:00am
Add AZN to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 215 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
AZN Stock Summary
- AZN has a higher market value than 98.77% of US stocks; more precisely, its current market capitalization is $106,395,780,000.
- With a price/earnings ratio of 86.71, Astrazeneca Plc P/E ratio is greater than that of about 95.3% of stocks in our set with positive earnings.
- In terms of volatility of its share price, AZN is more volatile than merely 6.49% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to Astrazeneca Plc are NVO, SNY, GSK, AMGN, and BMY.
- AZN's SEC filings can be seen here. And to visit Astrazeneca Plc's official web site, go to www.astrazeneca.com.
AZN Stock Price Chart More Charts
AZN Price/Volume Stats
| Current price | $42.47 | 52-week high | $51.55 |
| Prev. close | $42.36 | 52-week low | $36.15 |
| Day low | $40.69 | Volume | 6,783,100 |
| Day high | $43.13 | Avg. volume | 4,125,626 |
| 50-day MA | $46.56 | Dividend yield | 4.38% |
| 200-day MA | $45.54 | Market Cap | 111.46B |
Astrazeneca PLC (AZN) Company Bio
AstraZeneca plc engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. The company was founded in 1992 and is based in London, the United Kingdom.
AZN Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $42.47 | $15.07 | -64% |
We started the process of determining a valid price forecast for Astrazeneca Plc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Astrazeneca Plc ranked in the 19th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 64.17%. In terms of the factors that were most noteworthy in this DCF analysis for AZN, they are:
- The company's compound free cash flow growth rate over the past 5.81 years comes in at -0.12%; that's greater than only 15.57% of US stocks we're applying DCF forecasting to.
- The weighted average cost of capital for the company is 7. This value is greater than just 21.45% stocks in the Healthcare sector that generate free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -65% |
| 1% | -65% |
| 2% | -64% |
| 3% | -64% |
| 4% | -64% |
| 5% | -63% |
DHR, EW, TFX, CNMD, and HOLX can be thought of as valuation peers to AZN, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...